Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Immunotech Biopharm Ltd ( (HK:6978) ) is now available.
Immunotech Biopharm reported that all resolutions at its 30 April 2026 annual general meeting were approved by shareholders via poll, with 617,500,800 shares eligible to vote and no treasury or repurchased shares affecting the count. The company confirmed that there were no shareholders required to abstain or vote only against any item, indicating broad support for the meeting agenda.
Investors unanimously adopted the audited financial statements for the year ended 31 December 2025, re-elected the full slate of executive, non-executive and independent non-executive directors, and authorised the board to set directors’ pay. Deloitte Touche Tohmatsu was reappointed as auditor with board authority to fix its remuneration, underscoring continuity in governance and financial oversight for the company.
More about Immunotech Biopharm Ltd
Immunotech Biopharm Ltd is a Hong Kong-listed biopharmaceutical company incorporated in the Cayman Islands and traded under stock code 6978. The company focuses on developing and commercializing immunotherapy and related biotech treatments, targeting healthcare and life sciences markets in China and potentially broader international regions.
Average Trading Volume: 945,283
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$648.4M
Learn more about 6978 stock on TipRanks’ Stock Analysis page.